Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-05-13
- Target Recruit Count
- 32
- Registration Number
- NCT06385873
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- LaNova Medicines Zhejiang Co., Ltd.
- Target Recruit Count
- 375
- Registration Number
- NCT06351020
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Shanghai East Hospital, Shanghai, Shanghai, China
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 589
- Registration Number
- NCT06346392
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-01
- Target Recruit Count
- 32
- Registration Number
- NCT06339619
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT06308575
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
- Conditions
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Lei ZHAO
- Target Recruit Count
- 20
- Registration Number
- NCT06296563
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 170
- Registration Number
- NCT06281886
- Locations
- 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT06200233
- Locations
- 🇰🇷
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 35
- Registration Number
- NCT06181032
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 39
- Registration Number
- NCT06099821
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.